The global gastric cancer drugs market size reached USD 5.7 Billion in 2025. The analyst expects the market to reach USD 14.1 Billion by 2034, exhibiting a growth rate (CAGR) of 10.27% during 2026-2034. The expanding geriatric population and the rising incidence of obesity across the world are stimulating the market.
Trastuzumab is a monoclonal antibody that cures HER2-positive gastric cancer by targeting the HER2 protein, which improves patient outcomes and increases survival when combined with chemotherapy.
Parenteral administration, such as intravenous infusion, is widely utilized for chemotherapy and targeted therapies, providing quick drug absorption and efficacy in advanced gastric cancer cases.
Hospitals continue to be important end users, offering modern treatments such as chemotherapy, immunotherapy, and targeted medicines, as well as comprehensive cancer care through specialized oncology departments.
Asia-Pacific exhibits a clear dominance in the market driven by government initiatives aimed at improving cancer care and increasing healthcare spending. Furthermore, pharmaceutical corporations are also heavily spending on research and development, resulting in the introduction of new therapies such as targeted treatments and immunotherapy, which are gaining popularity.
GASTRIC CANCER DRUGS MARKET ANALYSIS:
- Major Market Drivers: The increasing frequency of both acute and chronic indications, the rising weight-related health issues, and the growing awareness about health consciousness are propelling the market.
- Key Market Trends: Rapid technological breakthroughs focused on the development of effective and tailored cancer treatments are contributing to the gastric cancer drugs market growth.
- Competitive Landscape: Some of the major market companies include Abbott Laboratories, Arog Pharamaceuticals Inc., Bristol-Myers Squibb Company, Daiichi Sankyo Company Limited, Eli Lilly and Company, F. Hoffmann-La Roche AG, Ono Pharmaceutical Co. Ltd., Sanofi S.A., Taiho Pharmaceutical Co. Ltd. (Otsuka Pharmaceutical Co. Ltd.), among many others.
- Geographical Trends: Asia-Pacific is currently dominating the market due to the rising prevalence of gastric cancer, attributed to factors such as poor dietary intake, Helicobacter pylori infections, and an aging population, which is increasing the need for effective treatments.
- Challenges and Opportunities: The high cost of advanced treatments is hampering the market. However, collaborations between governments and pharmaceutical corporations to lower costs and increase affordability will continue to catalyze the market over the forecast period.
GASTRIC CANCER DRUGS MARKET TRENDS:
Rise of Biosimilars
The development of biosimilars for gastric cancer medications is expanding, providing cost-effective alternatives to costly biologics and boosting access to innovative treatments in a variety of countries. In July 2024, Zydus Lifesciences received Mexican regulatory approval to market Mamitra, a trastuzumab biosimilar for breast and gastric cancer treatment, expanding its biosimilar portfolio.Growth in Advancements in Immunotherapy
The increasing focus on immunotherapy medications, particularly immune checkpoint inhibitors, is driving treatment research for gastric cancer. These medicines boost the immune system's reaction to cancer cells, providing intriguing alternatives to traditional chemotherapy. In October 2024, BeiGene launched the PD-1 cancer drug Tevimbra in the U.S. at a 10% discount to Merck's Keytruda after receiving FDA approval.Increase in Localized Clinical Trials
A surge in localized clinical trials is driving medication innovation and treatment protocols, with an emphasis on personalizing medicines to specific populations and genetic profiles, thereby boosting the effectiveness and relevance of gastric cancer treatments worldwide. In October 2024, a new study published in the New England Journal of Medicine revealed that gastric cancer patients treated with zolbetuximab, a medicine approved in Europe, had higher survival rates.GLOBAL GASTRIC CANCER DRUGS INDUSTRY SEGMENTATION:
This report provides an analysis of the key trends in each segment of the market, along with the market forecasts at the global, regional, and country levels for 2026-2034. The report has categorized the market based on type, route of administration, and end user.Breakup by Type:
- Doxorubicin Hydrochloride
- Sunitinib
- Docetaxel
- Mitomycin
- Fluorouracil
- Imatinib
- Trastuzumab
Currently, trastuzumab holds the largest gastric cancer drugs market share
The report has provided a detailed breakup and analysis of the market based on the type. This includes doxorubicin hydrochloride, sunitinib, docetaxel, mitomycin, fluorouracil, imatinib, and trastuzumab. According to the report, trastuzumab represented the largest market segmentation.Trastuzumab is a monoclonal antibody that cures HER2-positive gastric cancer by targeting the HER2 protein, which improves patient outcomes and increases survival when combined with chemotherapy.
Breakup by Route of Administration:
- Oral
- Parenteral
Among these, parenteral holds the largest gastric cancer drugs market size
The report has provided a detailed breakup and analysis of the market based on the route of administration. This includes oral and parenteral. According to the report, parenteral represented the largest market segmentation.Parenteral administration, such as intravenous infusion, is widely utilized for chemotherapy and targeted therapies, providing quick drug absorption and efficacy in advanced gastric cancer cases.
Breakup by End User:
- Hospitals
- Clinics
- Others
Currently, hospitals dominate the market with the largest gastric cancer drugs market share
The report has provided a detailed breakup and analysis of the market based on the end user. This includes hospitals, clinics, and others. According to the report, hospitals represented the largest market segmentation.Hospitals continue to be important end users, offering modern treatments such as chemotherapy, immunotherapy, and targeted medicines, as well as comprehensive cancer care through specialized oncology departments.
Breakup by Region:
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
Asia-Pacific leads in the gastric cancer drugs market growth
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia-Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, Asia-Pacific accounted for the largest gastric cancer drugs market share.Asia-Pacific exhibits a clear dominance in the market driven by government initiatives aimed at improving cancer care and increasing healthcare spending. Furthermore, pharmaceutical corporations are also heavily spending on research and development, resulting in the introduction of new therapies such as targeted treatments and immunotherapy, which are gaining popularity.
COMPETITIVE LANDSCAPE:
The report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major market companies have also been provided. Some of the key players in the market include:
- Abbott Laboratories
- Arog Pharamaceuticals Inc.
- Bristol-Myers Squibb Company
- Daiichi Sankyo Company Limited
- Eli Lilly and Company
- F. Hoffmann-La Roche AG
- Ono Pharmaceutical Co. Ltd.
- Sanofi S.A.
- Taiho Pharmaceutical Co. Ltd. (Otsuka Pharmaceutical Co. Ltd.)
Table of Contents
1 Preface3 Executive Summary11 Value Chain Analysis13 Price Analysis
2 Scope and Methodology
4 Introduction
5 Global Gastric Cancer Drugs Market
6 Market Breakup by Type
7 Market Breakup by Route of Administration
8 Market Breakup by End User
9 Market Breakup by Region
10 Drivers, Restraints, and Opportunities
12 Porters Five Forces Analysis
14 Competitive Landscape
List of Figures
List of Tables
Companies Mentioned
- Abbott Laboratories
- Arog Pharamaceuticals Inc.
- Bristol-Myers Squibb Company
- Daiichi Sankyo Company Limited
- Eli Lilly and Company
- F. Hoffmann-La Roche AG
- Ono Pharmaceutical Co. Ltd.
- Sanofi S.A.
- Taiho Pharmaceutical Co. Ltd. (Otsuka Pharmaceutical Co. Ltd.)
